Lp(a)：预防心血管事件的新星
Lp(a): A New Star of Preventing Cardiovascular Events
摘要: 随着对脂蛋白(a) [Lp(a)]的研究不断进展，Lp(a)已成为公认的增加心血管事件风险的独立危险因素。近期的研究表明，低密度脂蛋白水平达标的情况下仍会有心血管事件发生，这意味着有其他的危险因素作用于心血管疾病，也称为残余风险。本文旨在阐述Lp(a)与动脉粥样硬化性心血管疾病(Atherosclerotic Cardiovascular Disease, ASCVD)的研究进展和治疗血浆Lp(a)升高的药物进展。
Abstract: As the progress of lipoprotein(a) research, Lp(a) has become acknowledged an independent risk factor that affects cardiovascular disease. Recent studies have shown that regulating levels of low-density lipoprotein cholesterol (LDL-C) cannot fully control disease, suggesting there are other factors contributing to the risk of cardiovascular disease, which is named residual risks. This review aims to introduce the research progress between Lp(a) and ASCVD and the research progress of Lp(a) treatment methods.
文章引用：漆晨璐, 陈庆伟. Lp(a)：预防心血管事件的新星[J]. 临床医学进展, 2022, 12(12): 11051-11056. https://doi.org/10.12677/ACM.2022.12121592

参考文献

[1] Berg, K. (1965) A New Serum Type System in Man—The LD System. Vox Sanguinis, 10, 513-527. [Google Scholar] [CrossRef] 
[2] Dahlén, G. and Ramberg, U. (1974) Pre-Beta-1 Lipoprotein and Early Detection of Risk Factors for Coronary Heart Disease. Acta Medica Scandinavica, 195, 341-344. [Google Scholar] [CrossRef] [PubMed]
[3] Clarke, R., Peden, J., Hopewell, J., et al. (2009) Genetic Vari-ants Associated with Lp(a) Lipoprotein Level and Coronary Disease. The New England Journal of Medicine, 361, 2518-2528. [Google Scholar] [CrossRef] 
[4] Rao, F., Schork, A., Maihofer, A., et al. (2015) Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 1704-1711. [Google Scholar] [CrossRef] 
[5] Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. [Google Scholar] [CrossRef] [PubMed]
[6] Saleheen, D., Haycock, P.C., Zhao, W., et al. (2017) Apolipoprotein(a) Isoform Size, Lipoprotein(a) Concentration, and Coronary Artery Disease: A Mendelian Randomisation Analysis. The Lancet Diabetes & Endocrinology, 5, 524-533. [Google Scholar] [CrossRef] 
[7] Libby, P., Buring, J., Badimon, L., et al. (2019) Atherosclerosis. Nature Reviews Disease Primers, 5, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
[8] Ma, L., Chen, W., Gao, R., et al. (2020) China Cardiovascular Diseases Report 2018: An Updated Summary. Journal of Geriatric Cardiology: JGC, 17, 1-8.
[9] Mehta, A., Vasquez, N., Ayers, C.R., et al. (2022) Independent Association of Lipoprotein(a) and Coronary Artery Calcification with Atherosclerotic Cardiovascular Risk. Journal of the American College of Cardiology, 79, 757-768. [Google Scholar] [CrossRef] [PubMed]
[10] Kral, B., Kalyani, R., Yanek, L., et al. (2016) Relation of Plasma Lipopro-tein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans with a Family History of Early-Onset Coronary Artery Disease. The American Jour-nal of Cardiology, 118, 656-661. [Google Scholar] [CrossRef] [PubMed]
[11] Xia, J., Guo, C., Cao, H., et al. (2022) Impact of Lipoprotein(a) Level on Cardiometabolic Disease in the Chinese Population: The CHCN-BTH Study. Euro-pean Journal of Clinical Investigation, 52, e13689. [Google Scholar] [CrossRef] [PubMed]
[12] Kaiser, Y., Daghem, M., Tzolos, E., et al. (2022) Association of Lipoprotein(a) with Atherosclerotic Plaque Progression. Journal of the American College of Cardiology, 79, 223-233. [Google Scholar] [CrossRef] [PubMed]
[13] Reyes-Soffer, G., Ginsberg, H. and Ramakrishnan, R. (2017) The Metab-olism of Lipoprotein(a): An Ever-Evolving Story. Journal of Lipid Research, 58, 1756-1764. [Google Scholar] [CrossRef] 
[14] Capoulade, R., Chan, K., Yeang, C., et al. (2015) Oxidized Phospholipids, Lipo-protein(a), and Progression of Calcific Aortic Valve Stenosis. Journal of the American College of Cardiology, 66, 1236-1246. [Google Scholar] [CrossRef] [PubMed]
[15] Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., et al. (2009) Genet-ically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA, 301, 2331-2339. [Google Scholar] [CrossRef] [PubMed]
[16] Langsted, A., Kamstrup, P.R. and Nordestgaard, B.G. (2019) High Lipopro-tein(a) and High Risk of Mortality. European Heart Journal, 40, 2760-2770. [Google Scholar] [CrossRef] [PubMed]
[17] Cao, Y., Zhang, H., Jin, J., et al. (2021) Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thrombosis and Haemostasis, 121, 1161-1168. [Google Scholar] [CrossRef] [PubMed]
[18] Langsted, A., Nordestgaard, B.G. and Kamstrup, P.R. (2019) Elevated Lipopro-tein(a) and Risk of Ischemic Stroke. Journal of the American College of Cardiology, 74, 54-66. [Google Scholar] [CrossRef] [PubMed]
[19] Capoulade, R., Yeang, C., Chan, K.L., et al. (2018) Association of Mild to Moderate Aortic Valve Stenosis Progression with Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analy-sis of a Randomized Clinical Trial. JAMA Cardiology, 3, 1212-1217. [Google Scholar] [CrossRef] [PubMed]
[20] Guertin, J., Kaiser, Y., Manikpurage, H., et al. (2021) Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels with Cardi-ovascular Outcomes: Mendelian Randomization and Observational Analyses. Circulation Genomic and Precision Medicine, 14, e003271. [Google Scholar] [CrossRef] 
[21] Wong, N., Zhao, Y., Quek, R., et al. (2017) Residual Atherosclerotic Cardiovascular Disease Risk in Statin-Treated Adults: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Lipidolo-gy, 11, 1223-1233. [Google Scholar] [CrossRef] [PubMed]
[22] Hardy, J., Niman, S., Goldfaden, R.F., et al. (2022) A Review of the Clin-ical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. American Journal of Cardiovascular Drugs, 22, 47-54. [Google Scholar] [CrossRef] [PubMed]
[23] De Boer, L.M., Oorthuys, A.O.J., Wiegman, A., et al. (2021) Statin Therapy and Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis. European Journal of Preventive Cardiology, 29, 779-792. [Google Scholar] [CrossRef] 
[24] Tsimikas, S., Gordts, P., Nora, C., et al. (2020) Statin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. [Google Scholar] [CrossRef] [PubMed]
[25] Yeang, C., Wilkinson, M. and Tsimikas, S. (2016) Lipoprotein(a) and Oxi-dized Phospholipids in Calcific Aortic Valve Stenosis. Current Opinion in Cardiology, 31, 440-450. [Google Scholar] [CrossRef] 
[26] Viney, N.J., Van Capelleveen, J.C., Geary, R.S., et al. (2016) An-tisense Oligonucleotides Targeting Apolipoprotein(a) in People with Raised Lipoprotein(a): Two Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Trials. The Lancet (London, England), 388, 2239-2253. [Google Scholar] [CrossRef] 
[27] Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. The New England Journal of Medicine, 382, 244-255. [Google Scholar] [CrossRef] 
[28] Koren, M.J., Moriarty, P.M., Baum, S.J., et al. (2022) Preclinical Devel-opment and Phase 1 Trial of a Novel siRNA Targeting Lipoprotein(a). Nature Medicine, 28, 96-103. [Google Scholar] [CrossRef] [PubMed]
[29] Perrot, N., Verbeek, R., Sandhu, M., et al. (2017) Ideal Cardiovascular Health Influences Cardiovascular Disease Risk Associated with High Lipoprotein(a) Levels and Genotype: The EPIC-Norfolk Prospective Population Study. Atherosclerosis, 256, 47-52. [Google Scholar] [CrossRef] [PubMed]
[30] 北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.

为你推荐